Status:
RECRUITING
HIV Prevention With PrEP Among People on Opioid Replacement Therapy
Lead Sponsor:
Cara Spence
Collaborating Sponsors:
Gilead Sciences
Conditions:
HIV - Human Immunodeficiency Virus
Eligibility:
All Genders
16+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based pr...
Detailed Description
In Alberta and Saskatchewan, Canada, HIV acquisition is increasingly and predominantly seen in people who inject drugs (PWID). Less than 2% of this population are utilizing PrEP despite a high level o...
Eligibility Criteria
Inclusion
- HIV negative
- Ongoing behaviors with potential HIV exposure as assessed by a clinician
- Regularly engaged with their respective OAT program at least 3 days a week for the past 2 weeks
- Report willingness to return for follow-up visits
Exclusion
- Creatine clearance \<30 mL/min or any medical condition or medication known to be contraindicated with the use of Emtricitabine/Tenofovir Alafenamide (F/TAF) or Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)
- Taken PrEP within the last 24 hours at the time of screening or enrollment
- Deemed appropriate by a clinician for HIV Post-Exposure Prophylaxis at the time of screening or enrollment
Key Trial Info
Start Date :
August 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2027
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT07160075
Start Date
August 28 2025
End Date
September 1 2027
Last Update
October 7 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheldon M Chumir Health Centre
Calgary, Alberta, Canada, T2R 0X7
2
Queen City Wellness Pharmacy
Regina, Saskatchewan, Canada, S4P 0H7
3
Mayfair Drugs Pharmacy
Saskatoon, Saskatchewan, Canada, S7L 0V8
4
Pharmasave Riversdale Pharmacy
Saskatoon, Saskatchewan, Canada, S7M 0Y2